Electronic Health Records (EHRs) are comprehensive digital systems that capture, store, and manage patient healthcare information in real-world clinical settings. Unlike data collected in controlled clinical trial environments, EHRs represent actual medical encounters and treatment patterns as they occur in diverse healthcare delivery systems. EHRs serve as a critical infrastructure for generating Real-World Evidence (RWE) and Real-World Data (RWD), which inform decision-making across clinical practice, pharmaceutical development, and medical affairs operations 1).
EHRs function as longitudinal digital records documenting a patient's complete medical history across multiple encounters and healthcare settings. These systems integrate data from hospital systems, outpatient clinics, laboratory facilities, pharmacy records, and imaging centers. The scope of EHR data extends beyond basic demographic and diagnostic information to include clinical notes, medication histories, laboratory results, vital signs, procedural records, immunization histories, and treatment outcomes. This comprehensive approach distinguishes EHRs from legacy paper-based records and fragmented electronic systems, enabling holistic patient journey mapping and longitudinal outcome tracking 2).
The primary distinction between EHR data and controlled trial data lies in their operational context. Controlled trial data reflects carefully selected patient populations, standardized protocols, and rigorous follow-up procedures under investigator oversight. EHR data, conversely, captures unselected patient populations receiving routine clinical care with natural variation in treatment patterns, adherence, and follow-up intervals. This naturalistic data collection enables the generation of Real-World Evidence by documenting outcomes as they manifest in heterogeneous populations across diverse clinical settings.
EHRs enable Medical Affairs teams to assess drug effectiveness beyond licensed indications, identify safety signals in broader populations, and document long-term outcomes across extended follow-up periods. The data quality and completeness varies across healthcare systems based on implementation maturity, clinical workflow integration, and data governance practices. Key data elements for RWE applications include diagnosis codes, medication dispensing records, laboratory measurements, clinical outcomes, healthcare utilization patterns, and patient demographics. Advanced EHR implementations support structured data capture that facilitates standardized analysis and regulatory compliance 3).
A fundamental challenge in leveraging EHRs for RWE analysis involves interoperability barriers across fragmented healthcare IT systems. Large healthcare organizations typically operate multiple EHR platforms from different vendors (Epic, Cerner, Athenahealth), and integration with external data sources remains technically complex. Health Information Exchange (HIE) networks attempt to standardize data sharing through protocols such as Fast Healthcare Interoperability Resources (FHIR), though adoption remains inconsistent.
Data harmonization represents a significant operational challenge, as different EHR systems encode clinical concepts using varied data structures, coding standards, and terminology frameworks. Standardized vocabularies including ICD-10 diagnosis codes, CPT procedure codes, SNOMED CT, and RxNorm medication codes provide common mapping frameworks, yet local customizations and implementation variations persist across healthcare systems. Missing data, coding inconsistencies, and temporal gaps in clinical documentation further complicate analysis reliability. Medical Affairs organizations must implement robust data validation pipelines and engage clinical informatics expertise to ensure data quality sufficient for regulatory submissions 4).
EHR data supports multiple Medical Affairs functions including post-marketing surveillance, comparative effectiveness research, epidemiological studies, and health outcomes research. Regulatory agencies including the FDA increasingly accept EHR-derived evidence to support label updates, expanded indications, and safety communications. The 21st Century Cures Act and subsequent FDA guidance documents establish frameworks for EHR data utilization in regulatory submissions, though stringent data quality requirements necessitate comprehensive documentation of data governance, validation methodologies, and bias mitigation strategies.
Real-World Evidence derived from EHR data may supplement or occasionally replace traditional randomized controlled trial evidence for certain applications, particularly in post-authorization surveillance and long-term outcome assessment. Privacy protections, including de-identification methods complying with HIPAA Safe Harbor or Expert Determination standards, enable secondary use of EHR data for research while protecting patient confidentiality. Institutional Review Board (IRB) oversight and data use agreements establish appropriate governance frameworks for EHR-based research programs 5).